Home Cart Sign in  
Chemical Structure| 1181770-72-8 Chemical Structure| 1181770-72-8

Structure of EMD638683
CAS No.: 1181770-72-8

Chemical Structure| 1181770-72-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

EMD638683 is a highly selective SGK1 inhibitor with an IC50 value of 3 μM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of EMD638683

CAS No. :1181770-72-8
Formula : C18H18F2N2O4
M.W : 364.34
SMILES Code : CC1=C(CC)C(C(NNC(C(O)C2=CC(F)=CC(F)=C2)=O)=O)=CC=C1O
MDL No. :MFCD25541743
InChI Key :SSNAPUUWBPZGOY-UHFFFAOYSA-N
Pubchem ID :44182398

Safety of EMD638683

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse cortical neurons 10 μM 10 min To evaluate the effect of SGK inhibitors on NMDA currents using gramicidin-perforated patch-clamp recording, results showed that 10 μM EMD638683 significantly inhibited NMDA currents PMC4936920
Mouse cortical neurons 30 μM 10 min To evaluate the effect of SGK inhibitors on NMDA receptor-mediated neurotoxicity, results showed that EMD638683 significantly inhibited NMDA-induced cell injury and Ca2+ increase PMC4936920
Bone marrow mononuclear cells (BMMCs) 10 μM, 1 μM, 0 μM 14 days To study the effect of SGK inhibitor EMD638683 on osteoclasts in myeloma patients. Results showed that EMD638683 significantly inhibited the expression of SGK3 and p-SGK3 and reduced the area and resorption function of osteoclasts. PMC8330530
HCT116 cells 25 μM 24 hours Inhibition of SGK-1 kinase activity, resulting in decreased ATP production and cell viability in ECM-detached cells PMC4947665
MCF-10A cells 25 μM 24 hours Inhibition of SGK-1 kinase activity, resulting in decreased ATP production and cell viability in ECM-detached cells PMC4947665
Primary human aortic smooth muscle cells (HAoSMCs) 50 μM 24 hours EMD638683 inhibited phosphate-induced calcification and osteo-/chondrogenic transdifferentiation in HAoSMCs PMC6025998
Human aortic smooth muscle cells (HAoSMCs) 50 μM 24 hours Inhibited high glucose-induced osteogenic transdifferentiation and calcification of HAoSMCs PMC7583813
MCF-7 breast cancer cells 50 μM 24 hours Enhanced TAC-induced apoptotic response, activated caspase-3, and promoted early and late apoptosis PMC4622018
Primary murine hepatic stellate cells 1 μM 72 hours Inhibited Nedd4L phosphorylation, thereby suppressing Smad3 phosphorylation and collagen I production PMC11893157

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL6 mice Middle cerebral artery occlusion (MCAO) model Intracerebroventricular injection 1 mM Single administration, 30 min before MCAO To evaluate the effect of SGK inhibitors on ischemic brain injury, results showed that EMD638683 significantly reduced infarct volume PMC4936920
C57/B6 mice Angiotensin II-induced hypertensive mouse model Intraperitoneal injection 10 mg/kg Once daily for 2 weeks EMD638683 significantly reversed renal dysfunction and cardiac dysfunction in AngII-induced hypertensive mice, reduced renal and cardiac fibrosis, and inhibited Th17/Treg imbalance. PMC6262360
Mice High-fat diet-induced obesity model Intragastric 20 mg/kg Once daily for 6 months EMD638683 alleviated HFD-induced pulmonary fibrosis, reduced senescent cells and senescence-associated secretory phenotype (SASP) PMC10285269
Female C57BL/6 mice CCl4-induced liver fibrosis model Intraperitoneal injection 20mg/kg Injected at weeks 1, 3, and 6, lasting for 8 weeks Inhibited Nedd4L phosphorylation, alleviated liver fibrosis and inflammation, and improved gut microbiota PMC11893157
Mice Cholecalciferol overload model Oral gavage 300 mg/kg Twice daily for 3 days EMD638683 significantly reduced aortic calcification and stiffness PMC6025998
C57BL/6 mice Neonatal murine retinal vascularisation model Oral gavage 600 mg/kg For a week Investigate the effect of GJA4 mutation on vascular morphology, results showed that EMD638683 reversed the dilated venous lumen and elevated vascular density caused by GJA4 mutation. PMC10800255

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.74mL

0.55mL

0.27mL

13.72mL

2.74mL

1.37mL

27.45mL

5.49mL

2.74mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories